Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NVI7
UPID:
ATD3A_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NVI7; B3KPB3; D2K8Q1; G3V1I6; Q5SV23; Q8N275; Q96A50
Background:
ATPase family AAA domain-containing protein 3A plays a pivotal role in mitochondrial network organization, metabolism, and cell growth. It is essential for mitochondrial protein synthesis, DNA replication, and nucleoid stability. Additionally, it supports cholesterol channeling for steroidogenesis and has a role in antiviral innate immunity.
Therapeutic significance:
Linked to Harel-Yoon syndrome and a neonatal lethal pontocerebellar hypoplasia syndrome, understanding ATPase family AAA domain-containing protein 3A's role could unveil new therapeutic strategies for these disorders.